Focus:
News
-
11 August 2020
Ligand Pharmaceuticals agrees to acquire Pfenex for $516m
Ligand Pharmaceuticals has entered into a definitive agreement to acquire development and licencing biotechnology firm Pfenex in a deal valued at approximately $516m.
-
11 August 2020
Verastem to divest Copiktra rights to Secura Bio for up to $381m
Biopharmaceutical company Verastem has signed a definitive agreement to divest the global commercial and development rights for Copiktra (duvelisib) to Secura Bio in a deal valued at up to $381m.
-
11 August 2020
GigaGen develops new class of drugs to treat Covid-19
US-based biotechnology company GigaGen has developed a new class of drugs, called recombinant hyperimmunes, to potentially treat patients with Covid-19.
-
10 August 2020
Genentech secures FDA approval for Evrysdi to treat SMA
Roche unit Genentech has received approval from the US Food and Drug Administration (FDA) for Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) in patients aged two months and above.
-
10 August 2020
Pfizer signs multi-year deal to manufacture Gilead’s remdesivir
Pfizer has entered into a multi-year agreement to manufacture and supply Gilead Science’s experimental antiviral drug remdesivir, for the treatment of Covid-19 patients.
-
10 August 2020
Novavax partners with Takeda to develop Covid-19 vaccine in Japan
US-based biotechnology firm Novavax has partnered with Takeda Pharmaceutical to develop, manufacture and commercialise its Covid-19 vaccine candidate, NVX‑CoV2373, in Japan.
-
7 August 2020
US President orders government to buy drugs from domestic firms
US President Donald Trump has signed an executive order that requires the federal government to purchase some essential medicines from domestic manufacturers.
-
7 August 2020
Biogen and Denali sign Parkinson’s drug deal worth $2bn
Biogen has entered into a binding agreement with Denali Therapeutics to jointly develop and commercialise therapeutics for Parkinson’s disease.
-
7 August 2020
AstraZeneca signs first deal to supply Covid-19 vaccine in China
AstraZeneca has partnered with Shenzhen Kangtai Biological Products to manufacture its Covid-19 vaccine candidate in mainland China, marking its first deal to supply in the country.
-
6 August 2020
US seeks nearly $13bn from Purdue Pharma over opioid claims
The US Department of Justice is seeking approximately $13bn in criminal and civil penalties from Purdue Pharma over opioid claims filed against the company.